KLRB1 and glioma: Specifically, genetic inactivation of KLRB1 or antibody-mediated CD161 blockade enhances T cell-mediated killing of glioma cells in vitro and their anti-tumor function in vivo8, identifying CD161-CLEC2D pathway as a potential target for immunotherapy.